Novavax Inc (NVAX)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$7.10
Buy
$7.15
$-0.46 (-6.23%)
Prices updated at 28 May 2025, 09:49 EDT
| Prices minimum 15 mins delay
Prices in USD
Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
Ms. Margaret G. McGlynn
CEO
Mr. John C. Jacobs
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
1,992
Head office
700 Quince Orchard Road
Gaithersburg
United States
20878
Key personnel
Owner name | Salary |
---|---|
Ms. Margaret G. McGlynn Chairman of the Board | 0.08m |
Mr. John J. Trizzino Co-President and Chief Operating Officer | 0.58m |
Mr. Charles W. Newton Independent Director | - |
Dr. John W. Shiver, PhD Independent Director | - |
Dr. Gregg H. Alton, J.D. Independent Director | 0.07m |
Mr. Richard J. Rodgers Independent Director | 0.09m |
Mr. David M. Mott Independent Director | 0.08m |
Mr. Mark J. Casey Executive Vice President, Chief Legal Officer and Corporate Secretary | 0.56m |
Dr. Richard H. Douglas, PhD Independent Director | 0.08m |
Ms. Rachel K. King Independent Director | 0.07m |
Mr. John C. Jacobs Director, President and Chief Executive Officer | 0.75m |
Mr. James P. Kelly Executive Vice President, Chief Financial Officer, Treasurer and Principal Accounting Officer | 0.55m |
Ms. Elaine O'Hara Executive Vice President and Chief Strategy Officer | 0.54m |
Dr. Ruxandra Draghia-Akli Executive Vice President and Head of Research and Development | - |
Top 5 shareholders
Owner name | No. of shares |
---|---|
Vanguard Group Inc | 15,674,378 |
Vanguard Group Inc. ( Junked) | 15,430,034 |
BlackRock Inc | 12,967,029 |
Shah Capital Management | 11,131,846 |
State Street Corp | 7,039,158 |
Director dealings
Date | Action |
---|---|
31 Dec 2024 | - |
24 Dec 2024 | - |
13 Dec 2024 | - |
11 Dec 2024 | - |
11 Dec 2024 | - |
11 Dec 2024 | - |
11 Nov 2024 | - |
11 Nov 2024 | - |
29 Oct 2024 | - |
29 Oct 2024 | - |
19 Aug 2024 | - |
19 Aug 2024 | - |
19 Aug 2024 | - |
21 Jun 2024 | - |
18 Jun 2024 | - |
18 Jun 2024 | - |
17 Jun 2024 | - |
17 Jun 2024 | - |
17 Jun 2024 | - |
17 Jun 2024 | - |
Please note that past performance is not a reliable indicator of future returns.